Clinical trial
A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg Dose of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Patients With Excess of Abdominal Fat Accumulation
NCT00123253 is registered in ClinicalTrials.gov with Theratechnologies as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg Dose of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Patients With Excess of Abdominal Fat Accumulation
- Lead sponsor
- Theratechnologies
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 30, 2005
- Completion date
- April 30, 2007
- Enrollment
- 412 (actual)
- Sites
- 42
Conditions
As the registry lists them; a condition with its own page is linked.